Less well known, on June 12, 2023, AAN again asked CMS to reconsider the NCD. As far as I know, there's no reply yet. Here's the nine-page, June 12, AAN letter to CMS.
Tidbit - the letter is addressed to Ms. Syrek-Jensen as head of Coverage; she's now moved to a different position in the CMS quality and coverage division.
This week, CMS announced that it would require a bare-bones clinical registry (with fields like doctor name, patient name, and drug name) via a portal it will open as soon as Leqembi gets FDA full approval (any day now). I wrote two brief blogs about the registry announcement.
Blog #1 - Amyloid tests in the registry.
Blog #2 - Data in the registry.